Virtual Reality in the Treatment of Pelvic Floor Dysfunction in Women With Multiple Sclerosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Virtual reality, Neuromodulation of the tibialis posterior nerve, Pelvic floor muscle training.
- Who it may be relevant to
- Registry conditions: Multiple Sclerosis. Basic parameters: 18 years — 65 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effects of Virtual Reality in the Treatment of Pelvic Floor Dysfunction in Women With Multiple Sclerosis: A Randomized Clinical Trial
Overview
The purpose of the current randomized clinical trial was to compare the effectiveness of virtual reality versus posterior tibial nerve stimulation on the improvement of pelvic floor dysfunctions in women with multiple sclerosis.
Detailed description
* Design: Randomized Clinical Trial. Objective: to determine the effects of virtual reality versus posterior tibial nerve stimulation and muscle activation exercises on the improvement of pelvic floor dysfunctions in women with multiple sclerosis. * Methods and Measures: forty five women will be randomly assigned to one of three groups. * Intervention: For 8-week, the group 1 will undergo treatment with virtual reality (2/week), the group 2 will receive posterior tibial nerve stimulation (2/week) and the group 3 will receive muscle activation exercises of the pelvic floor. * Main Outcome Measures: assessment of pelvic floor muscles function (strength and muscle tone), urodynamic studies, and validated questionnaires data will be collected at baseline, and 1 week after the last therapy application. Mixed-model analyses of variance will be used to examine the effects of the treatment on each outcome measure.
Interventions
- Other Virtual reality
Participants receive virtual reality treatment, 8 weeks of treatment/ 2 times a week - Other Neuromodulation of the tibialis posterior nerve
Participants receive neuromodulation of the tibialis posterior nerve8 weeks of treatment/ 2 times a week/ 30 minutes - Other Pelvic floor muscle training
Participants receive pelvic floor muscle training 5 times a day for 9 weeks
Primary outcome measures
- Pelvic floor strength [Time frame: At baseline, immediately after the intervention, and 4 weeks] [Safety Issue: No] It is a device for measuring the strength of the pelvic floor, to which a speculum is adapted. measure force in newtons]
Secondary outcome measures (4)
- Australian pelvic floor questionnaire: [Time frame: At baseline, immediately after the intervention, and 4 weeks]
- Multiple Sclerosis Quality of Life-54 (MSQOL-54): [Time frame: At baseline, immediately after the intervention, and 4 weeks]
- Euroqol [Time frame: At baseline, immediately after the intervention, and 4 weeks]
- SF12 [Time frame: At baseline, immediately after the intervention, and 4 weeks]
Eligibility criteria
Inclusion criteria
- Diagnosis of multiple sclerosis
- Presence of pelvic floor dysfunction
- Acceptance participation
- Not undergoing another physical therapy treatment
Exclusion criteria
- Non-acceptance of participation
- Mental illness
- Interruption of adherence to protocolized treatment sessions
- Indication of surgical treatment in the pelvic floor
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06576947 · UALBIO2024/015